Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand

Safety and immunogenicity of CoronaVac and ChAdOx1 heterologous prime-boost vaccines in an overweight population in Chiang Mai, Thailand

Background: In early 2021, the Ministry of Public Health of Thailand announced heterologous regimens for COVID-19 vaccines using CoronaVac as the first dose followed by ChAdOx1 nCoV-19 at 3 weeks apart. Priority was given to individuals above 60 years old and those who had seven underlying condition...

Full description

Bibliographic Details
Main Authors: Kriangkrai Chawansuntati, Supachai Sakkhachornphop, Sayamon Hongjaisee, Saranta Freeouf, Patumrat Sripan, Nattaya Nusartsang, Romanee Chaiwarith, Tavitiya Sudjaritruk, Khuanchai Supparatpinyo, Jiraprapa Wipasa
Format: Article
Language:English
Published: Elsevier 2024-06-01
Series:Vaccine: X
Subjects:
Coronavirus disease (COVID-19)
CoronaVac
ChAdOx1
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Neutralizing antibodies
Online Access:http://www.sciencedirect.com/science/article/pii/S2590136224000482

Internet

http://www.sciencedirect.com/science/article/pii/S2590136224000482

Similar Items